Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 12, 2017

Study Completion Date

July 12, 2017

Conditions
Secondary Progressive Multiple Sclerosis
Interventions
PROCEDURE

Blood Draw

Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.

PROCEDURE

CSF collection by lumbar puncture (Optional)

For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.

Trial Locations (13)

11772

South Shore Neurologic Associates - Multiple Sclerosis Care Center, Patchogue

28207

Carolinas Medical Center (CMC), Charlotte

44195

Cleveland Clinic: Mellen Center for Multiple Sclerosis, Cleveland

48109

University of Michigan Health System -Multiple Sclerosis Center, Ann Arbor

48202

Henry Ford Health System, Detroit

55422

Minneapolis Clinic of Neurology, Golden Valley

80045

University of Colorado, Aurora

87131

University of New Mexico: Health Sciences Center, Albuquerque

90033

University of Southern California, Los Angeles

94705

Jordan Research & Education Institute: Sutter Alta Bates Summit, Berkeley

95817

University of California, Davis, Sacramento

97225

Providence Multiple Sclerosis Center, Portland

98122

Swedish Neuroscience Institute, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Autoimmunity Centers of Excellence

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH